Grant will focus on identifying, validating food allergy biomarkers that impact food allergy research, from predictions to monitoring and beyond
McLean, Va. (January 7, 2020) – Today, the world’s largest private funder of food allergy research, announced it will co-sponsor a $500 thousand Biomarker Research Grant with Janssen’s World Without Disease Accelerator*, part of the Janssen Pharmaceutical Companies of Johnson & Johnson. The Biomarker Research Grant is focused on identifying and validating novel food allergy biomarkers that will impact many aspects of food allergy research, from predictions to monitoring and beyond.
“The Biomarker Research Grant not only supports FARE’s goal to better understand the food allergy epidemic but will also aide us in hopefully identifying new and promising treatments and, eventually, finding a cure,” said Lisa Gable, chief executive officer of FARE. “We are proud to work with Janssen on this initiative and look forward to our collaborative effort working towards changing the face of food allergy research.”
Biomarker research has the potential to make a real and significant impact for the 32 million Americans living with food allergies. Currently, patients with food allergies have limited access to treatment options and must be constantly diligent to avoid their allergens and, in the event of accidental exposure, administer epinephrine and quickly visit the emergency room. According to recent FARE-supported research, medical claims with diagnoses of life-threatening anaphylactic food reactions rose nearly 400 percent nationwide between 2007 and 2016.
The Biomarker Research Grant is aimed at addressing early childhood medical conditions to encourage healthy development, while preventing and intercepting chronic diseases, a focus of FARE and Janssen’s World Without Disease Accelerator group. Childhood-onset food allergy, a complex disease involving multiple body systems, still requires much more research to fully understand its root causes. Such research will accelerate innovation in food allergy treatment, whether by prevention to stop disease onset, interception to arrest disease development, or with a cure to eliminate food allergy completely and restore health.
FARE will contribute $250,000 with Janssen matching to bring the total investment to a half-million dollars. FARE will be launching a formal request for applications (RFA) to the Biomarker Research Grant in early 2020.
*The legal entity to the agreement with FARE is Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
For general inquiries, please call 800-929-4040.
Food Allergy Research & Education (FARE) is the world’s leading food allergy advocacy organization and the largest private funder of food allergy research. Our mission is to improve the quality of life and the health of individuals with food allergies, and to provide them hope through the promise of new treatments. FARE is transforming the future of food allergy through innovative initiatives that will lead to increased awareness, new and improved treatments and prevention strategies, effective policies and legislation and novel approaches to managing the disease. For more information, please visit www.foodallergy.org. To join FARE’s transformative five-year fundraising and awareness campaign, Contains: Courage™, supporting families living with food allergies and educating ALL communities about the disease, visit www.foodallergy.org/containscourage.
Courage at Congress Campaign: FARE Needs YOUR Help